HAE240920C55000
- 21.70
- 0.000.00%
Haemonetics Newsroom
Haemonetics Technology Chief to Exit
C.L. King Initiates Haemonetics(HAE.US) With Buy Rating, Announces Target Price $116
BofA Securities Initiates Haemonetics(HAE.US) With Hold Rating, Announces Target Price $85
Haemonetics Price Target Announced at $85.00/Share by B of A Securities
BTIG Initiates Haemonetics(HAE.US) With Buy Rating, Announces Target Price $112
Express News | Haemonetics Corp : Btig Initiates Coverage With Buy Rating; Price Target $112
Haemonetics: A Solid Investment in MedTech With Promising Growth and Valuation Upside
Haemonetics (NYSE:HAE) Shareholders Have Endured a 38% Loss From Investing in the Stock Five Years Ago
After Plunging -15.88% in 4 Weeks, Here's Why the Trend Might Reverse for Haemonetics (HAE)
Implied Volatility Surging for Haemonetics (HAE) Stock Options
Haemonetics Is Maintained at Neutral by Citigroup
Express News | Haemonetics Corp : Citigroup Cuts Target Price to $85 From $94
Citi Maintains Haemonetics(HAE.US) With Hold Rating, Cuts Target Price to $85
Top 3 Health Care Stocks That Are Set To Fly This Quarter
Haemonetics' Vascade MVP XL Vascular Closure System Enters US Market
Sector Update: Health Care Stocks Rise in Afternoon Trading
Haemonetics Announces Full Market Release for VASCADE MVP XL Vascular Closure System
Express News | JMP Securities Reiterates Market Outperform on Haemonetics, Maintains $125 Price Target
Haemonetics Corporation: Strong Growth and Innovation Justify a Buy Rating
Haemonetics (HAE) Q1 Earnings Miss Estimates, Gross Margin Rises